FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Region

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 15, 2023--

Related Keywords

United States ,California ,South San Francisco ,Canada ,Sweden ,Swedish ,Levi Garraway ,Krish Patel ,Lindsey Mathias ,Informationandmedication Guideor ,Loren Kalm ,Cem Mangir ,Bruno Eschli ,Global Product Development ,Drug Administration ,Roche Group ,Lymphoma Program ,Genentech Access Solutions ,Genentech ,Swedish Cancer Institute In Seattle ,Global Product ,Swedish Cancer Institute ,Columvi Phase ,New England Journal ,European Medicines Agency ,Medicinal Products ,Human Use ,Genentech Access ,Largeb Cell Lymphoma Arising ,Cytokine Release Syndrome ,Columvi Patient Wallet Card ,Important Safety Information ,Serious Side Effects ,Prescribing Information ,Medication Guide ,Prescribing Informationandmedication Guideor ,Blood Cell Counts ,Prescribing Informationand ,Important Safety ,Media Contact ,Business Wire ,Region ,